X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IBI362
Therapeutic Area: Nutrition and Weight Loss Product Name: LY3305677
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2021
Details:
IBI362, a glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist used to assess the efficacy and safety of IBI362 in overweight or obese subjects in China.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BI 456906
Therapeutic Area: Nutrition and Weight Loss Product Name: BI 456906
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Zealand Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2021
Details:
The Phase 2 randomized double-blind placebo-controlled dose-finding trial will evaluate GLP-1/glucagon dual agonist, BI 456906, in people with obesity or who are overweight with a BMI 27 kg/m2 or higher without diabetes.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
